Although GIP also exerts potent incretin-like effects on β cells in healthy individuals, the actions of GIP are impaired in patients with diabetes mellitus, which limits the possibilities of its ...

诺和诺德负责开发事务的行政副总裁Martin Holst Lange表示，9月11日公布的第一阶段临床试验结果将表明，减肥药Amycretin（一种新型口服GLP-1受体和胰淀素受体长效共激动剂）存在与其他基于肠促胰岛素（incretin）的减肥药类似的副作用。我们看到，减肥药效果不错，同时存在副作用。在为期12周的研究中，受试病患接受最高2*50 mg剂量后减重13.1%。公司计划展开更大样本量 ...

BMO Capital维持对Eli Lilly股票（NYSE:LLY）的"优于大盘"评级，目标价为1,101.00美元。该公司强调了Eli ...

A new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...

We aimed to investigate whether the reduced incretin effect observed in patients with type 2 diabetes is a primary event in the pathogenesis of type 2 diabetes or a consequence of the diabetic state.

【诺和诺德行政副总裁：我司减肥药存在典型的副作用】诺和诺德负责开发事务的行政副总裁Martin Holst Lange表示，9月11日公布的第一阶段临床试验结果将表明，减肥药Amycretin（一种新型口服GLP-1受体和胰淀素受体长效共激动剂）存在与其他基于肠促胰岛素（incretin）的减肥药类似的副作用。我们看到，减肥药效果不错，同时存在副作用。在为期12周的研究中，受试病患接受最高2*50 ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Incretin therapies based on GLP-1 receptor agonism aid in the loss of weight in obesity, but a relevant part of this loss (25%-40%) is attributed to loss of lean muscle mass, which raises the risk of ...

周一，根据BTIG最新报告，Zealand Pharma A/S (ZEAL:DC) (OTC: ZLDPF)的股价目标从1,050丹麦克朗上调至1,100丹麦克朗，同时维持买入评级。此次调整源于该公司肥胖治疗药物dapiglutide的早期结果令人鼓舞。 接受dapiglutide治疗13周的患者平均体重减少6.2%，而安慰剂组平均体重增加2.1%。这个8.3%的安慰剂校正体重减轻结果被认为是积 ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

That’s less than half the list price of other incretin medicines. Back To Top ...

We need to take stock of the promises and limitations of new “miracle” weight loss drugs and treat the cause of weight gain, ...